CEMP : Summary for Cempra, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs.

Cempra, Inc. (CEMP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.050.00 (0.00%)
At close: 4:00PM EDT
People also watch
TTPHESPRCLVSFOLDPTLA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.05
Open4.10
Bid2.95 x 5500
Ask4.75 x 200
Day's Range3.95 - 4.25
52 Week Range2.55 - 26.95
Volume1,024,344
Avg. Volume2,762,166
Market Cap212.19M
Beta1.01
PE Ratio (TTM)-1.73
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube4 days ago

    Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Cempra, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Cempra, Inc. – Johnson & Johnson, Innoviva, Inc., KaloBios Pharmaceuticals Inc, Emergent BioSolutions Inc. and PharmAthene, Inc. (JNJ-US, INVA-US, KBIO-US, EBS-US and PIP-US) that have also reported for this ... Read more (Read more...)

  • Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
    Capital Cube10 days ago

    Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017

    Categories: Yahoo Finance Get free summary analysis Cempra, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Cempra, Inc. – Johnson & Johnson, Innoviva, Inc. and Emergent BioSolutions Inc. (JNJ-US, INVA-US and EBS-US) that have also reported for this period. Highlights Year-on-year change in operating cash ... Read more (Read more...)

  • American City Business Journals11 days ago

    With $230M in cash, Cempra’s “strategic business options” wide-ranging

    With $231.6 million in cash as of Dec. 31, Cempra (CEMP) says its “review of strategic business options,” will be wide-ranging. The Chapel Hill-based company said Monday that it has retained Morgan Stanley as financial advisor for the review, which was announced at the same time as a 67 percent workforce reduction at the end of February . “Our corporate restructuring was implemented to enable us to conserve our financial resources,” Cempra stated at the time.